Keywords: fda, clears, merck, kgaa/forest, campral, food, drug
FDA clears Merck KGaA/Forest's Campral
Article | 09 August 2004
The US Food and Drug Administration has approved Merck KGaA/ForestLaboratories' Campral (acamprosate calcium) delayed-release tablets for the maintenance of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
